Tesaro's ovarian cancer drug study succeeds, shares soar

(Reuters) – Tesaro Inc said its experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares to a record high.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *